![Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41537-020-00127-y/MediaObjects/41537_2020_127_Fig1_HTML.png)
Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia
![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005533/en/850837/23/MedinCell_LOGO.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
![Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021 Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021](https://pharma.nridigital.com/pharma/pharma_feb21/teva_medincell_lai_schizophrenia/1118760/__screenshot.jpg)
Teva and MedinCell looking to enter LAI schizophrenia market - Pharma Technology Focus | Issue 103 | February 2021
![Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire](https://mms.businesswire.com/media/20210107005469/en/739014/22/teva_RGB_JPEG.jpg)
Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia | Business Wire
![PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M. PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M.](https://0.academia-photos.com/attachment_thumbnails/35501918/mini_magick20190314-21389-1n2isxh.png?1552554786)
PDF) A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP) | abraham nussbaum and M.
![Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena](https://www.clinicaltrialsarena.com/wp-content/uploads/sites/22/2020/11/Glenmark-1038x778.jpg)
Teva and MedinCell Looking to Enter Increasingly Competitive LAI Schizophrenia Market - Clinical Trials Arena
![Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia Efficacy and safety of once-monthly Risperidone ISM® in schizophrenic patients with an acute exacerbation | Schizophrenia](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41537-020-00127-y/MediaObjects/41537_2020_127_Fig3_HTML.png)